Half-year report · HY
4587.TEDINET S100YVU6
Period2026-01-01 → 2026-06-30
Filed2026-08-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.2bn | 2026-01-01 → 2026-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥18.5bn | 2025-01-01 → 2025-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥8.5bn | 2025-01-01 → 2025-06-30 | Cons. | Revenue IFRS |
| Operating income | −¥2.5bn | 2026-01-01 → 2026-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | −¥2.6bn | 2025-01-01 → 2025-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥2.7bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥5.3bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥2.9bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥2.0bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥3.7bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥2.1bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥2.0bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss IFRS |
| Net income | −¥3.7bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥2.1bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥72.2bn | at 2026-06-30 | Cons. | Assets IFRS |
| Total assets | ¥77.0bn | at 2025-12-31 | Cons. | Assets IFRS |
| Total assets | ¥78.5bn | at 2025-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥23.7bn | at 2026-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥25.5bn | at 2025-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥48.6bn | at 2026-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥51.5bn | at 2025-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥53.7bn | at 2025-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥56.8bn | at 2024-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥48.6bn | at 2026-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥51.5bn | at 2025-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥53.7bn | at 2025-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥23.6bn | at 2026-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥28.7bn | at 2025-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥33.3bn | at 2025-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥48.1bn | at 2024-12-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥1.8bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥13.3bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥11.0bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥614m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥2.1bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥1.3bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥2.7bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥4.1bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥2.5bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-15.51 | 2026-01-01 → 2026-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-28.99 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-16.4 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-15.51 | 2026-01-01 → 2026-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-28.99 | 2025-01-01 → 2025-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-16.4 | 2025-01-01 → 2025-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 67.2% | at 2026-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 66.9% | at 2025-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.3% | at 2025-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2026-01-01 → 2026-06-30 | −¥512m |
| Reconciling Itemsreconciling | revenue intersegment | 2026-01-01 → 2026-06-30 | −¥512m |
| Drug Discovery And Development Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥1.2bn |
| Drug Discovery And Development Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥1.2bn |
| Drug Discovery And Development Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | −¥2.7bn |
| Radiopharmaceuticals Businessreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥8.5bn |
| Radiopharmaceuticals Businessreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥8.0bn |
| Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥512m |
| Radiopharmaceuticals Businessreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥242m |
| —segment total | revenue | 2026-01-01 → 2026-06-30 | ¥9.7bn |
| —segment total | revenue external | 2026-01-01 → 2026-06-30 | ¥9.2bn |
| —segment total | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥512m |
| —segment total | segment profit | 2026-01-01 → 2026-06-30 | −¥2.5bn |
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-06-30 | −¥453m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-06-30 | −¥453m |
| Drug Discovery And Development Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥761m |
| Drug Discovery And Development Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥761m |
| Drug Discovery And Development Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥3.0bn |
| Radiopharmaceuticals Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥8.2bn |
| Radiopharmaceuticals Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥7.8bn |
| Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥453m |
| Radiopharmaceuticals Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥436m |
| —segment total | revenue | 2025-01-01 → 2025-06-30 | ¥9.0bn |
| —segment total | revenue external | 2025-01-01 → 2025-06-30 | ¥8.5bn |
| —segment total | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥453m |
| —segment total | segment profit | 2025-01-01 → 2025-06-30 | −¥2.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 571
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenue IFRS | InterimDuration | 9226971000 | JPY |
| Segment profit loss IFRS | InterimDuration_jpcrp040300-ssr_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember | -2731999000 | JPY |
| Segment profit loss IFRS | InterimDuration_jpcrp040300-ssr_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember | 242216000 | JPY |
| Segment profit loss IFRS | InterimDuration_ReportableSegmentsMember | -2489782000 | JPY |
| Segment profit loss IFRS | InterimDuration_ReconcilingItemsMember | － | JPY |
| Segment profit loss IFRS | InterimDuration | -2489782000 | JPY |
| Business combination related expenses IFRS | InterimDuration | 45000000 | JPY |
| Operating profit loss IFRS | InterimDuration | -2534782000 | JPY |
| Finance income IFRS | InterimDuration | 135053000 | JPY |
| Finance costs IFRS | InterimDuration | 258737000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | InterimDuration | -1323000 | JPY |
| Profit loss before tax IFRS | InterimDuration | -2659790000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2026-08-12 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第21期中(自 2026年１月１日 至 2026年６月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)ペプチドリーム株式会社 | |
| Company name in english cover page | FilingDateInstant | PeptiDream Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長CEO リード・パトリック | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)神奈川県川崎市川崎区殿町三丁目25番23号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 044(270)1300 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)ＩＲ広報ヴァイスプレジデント 沖本 優子 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)神奈川県川崎市川崎区殿町三丁目25番23号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 044(223)6612 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)ＩＲ広報ヴァイスプレジデント 沖本 優子 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E27486 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45870 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)ペプチドリーム株式会社 | |
| Filer name in english | FilingDateInstant | PeptiDream Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2026-01-01 | |
| Current period end date | FilingDateInstant | 2026-06-30 | |
| Type of current period | FilingDateInstant | HY | |
| Current fiscal year end date | FilingDateInstant | 2026-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2025-01-01 | |
| Comparative period end date | FilingDateInstant | 2025-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2025-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |